{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%28PBO%29&page=5",
    "query": {
      "intervention": "placebo (PBO)",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 164,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%28PBO%29&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%28PBO%29&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T11:37:17.237Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04593784",
      "title": "Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ciraparantag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Point-of-Care Coagulometer (investigational device)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 41,
      "start_date": "2021-10-13",
      "completion_date": "2023-08-26",
      "has_results": true,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 3,
      "location_summary": "South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Secaucus",
          "state": "New Jersey"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04593784"
    },
    {
      "nct_id": "NCT06970301",
      "title": "A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Study Participants"
      ],
      "interventions": [
        {
          "name": "glovadalen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-04-28",
      "completion_date": "2026-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06970301"
    },
    {
      "nct_id": "NCT05004727",
      "title": "Multi-Center PAMPA Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2022-02-16",
      "completion_date": "2028-11-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Rochester, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004727"
    },
    {
      "nct_id": "NCT01377623",
      "title": "Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Stenosis",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine group",
          "type": "DRUG"
        },
        {
          "name": "Placebo group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2010-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01377623"
    },
    {
      "nct_id": "NCT02537574",
      "title": "Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "NTX/BUP",
          "type": "DRUG"
        },
        {
          "name": "NTX/PBO-B",
          "type": "DRUG"
        },
        {
          "name": "PBO-N/PBO-B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 380,
      "start_date": "2015-08",
      "completion_date": "2017-01-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-06",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 20,
      "location_summary": "Oceanside, California • Orange, California • Lauderhill, Florida + 17 more",
      "locations": [
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Lauderhill",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Oakland Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02537574"
    },
    {
      "nct_id": "NCT03247530",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "200mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 477,
      "start_date": "2017-10-20",
      "completion_date": "2018-09-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 7,
      "location_summary": "Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03247530"
    },
    {
      "nct_id": "NCT04622007",
      "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tomivosertib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Effector Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2021-06-02",
      "completion_date": "2024-12-09",
      "has_results": false,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 131,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04622007"
    },
    {
      "nct_id": "NCT05083312",
      "title": "Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "APT-1011",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ellodi Pharmaceuticals, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-30",
      "completion_date": "2022-09-05",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Boston, Massachusetts",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05083312"
    },
    {
      "nct_id": "NCT03370133",
      "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Psoriasis",
        "Moderate to Severe Chronic Plaque Psoriasis",
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 567,
      "start_date": "2017-12-06",
      "completion_date": "2019-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370133"
    },
    {
      "nct_id": "NCT01096979",
      "title": "An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Subcutaneous Abdominal Adiposity"
      ],
      "interventions": [
        {
          "name": "LIPO-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neothetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2009-10",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2015-03-26",
      "last_synced_at": "2026-11-03T11:37:17.237Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • San Diego, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01096979"
    }
  ]
}